ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more
ADMA Biologics, Inc. is a commercial-stage biopharmaceutical company that manufactures, markets, and develops specialty plasma-derived therapies for immunodeficient patients. Its flagship product, ASCENIV, is an immune globulin treatment for primary humoral immunodeficiency, while BIVIGAM is an intravenous immune globulin used in similar patient populations. The company also markets Nabi-HB, a hepatitis B immune globulin.
The business is vertically integrated, operating its own plasma collection centers and FDA-approved manufacturing facilities in Boca Raton, Florida. That end-to-end control over sourcing and production is a key competitive differentiator, helping the company manage supply, quality, and manufacturing costs. Investors follow ADMA closely for its ASCENIV growth trajectory, expanding gross margins, and disciplined capital-allocation strategy.
Over the trailing 30-day period, ADMA shares moved from a closing price near $10.73 to roughly $13.68, a gain of about 27%. Much of that move came in a single session following the company's third-quarter earnings release, when the stock jumped more than 25% on sharply elevated trading volume.
The broader trend has been even stronger. Measured over the last quarter, spanning roughly three months, the stock climbed from around $9.40–$9.50 in mid-August to its current level, representing an advance of approximately 44%. The move reflects a shift in sentiment from a challenging first half of the year toward renewed confidence in the company's commercial momentum and profitability.
The primary catalyst was ADMA's third-quarter 2026 financial results, reported in early November. Total revenue reached $141.1 million, up 5% year over year and 13% sequentially, beating consensus estimates by roughly $3 million. GAAP earnings per share of $0.22 also came in ahead of expectations.
The standout was ASCENIV, which generated $124.7 million in revenue, an increase of 31% year over year and 21% sequentially. Management attributed the strength to expanding physician adoption, new patient starts, and growing end-user utilization. Gross margin expanded to 71%, up from 56% a year earlier, driven by favorable product mix and yield-enhanced manufacturing.
Alongside the results, ADMA raised its full-year 2026 outlook, increasing its minimum adjusted EBITDA guidance to at least $275 million (from $265 million) and adjusted net income to at least $180 million (from $170 million), while reiterating revenue guidance of at least $530 million. The company also reported constructive FDA feedback on its SG-001 pre-IND package, an investigational pneumococcal hyperimmune globulin candidate with an estimated $300–500 million annual revenue opportunity.
The quarterly advance reflects a broader turnaround narrative. After a difficult first half of 2026, investor confidence rebuilt around ASCENIV's accelerating demand, meaningful margin expansion, and improving profitability. Rising gross margins and strong operating leverage translated revenue growth into faster earnings growth, while continued share repurchases—totaling 16.5 million shares year-to-date—reduced the share count and supported per-share results.
Progress on the SG-001 pipeline, aided by the company's proprietary ADMAlytics AI platform, added a longer-term growth dimension. However, the quarter also carried mixed signals: BIVIGAM revenue declined to $15.4 million as competitive pricing pressures persisted in the standard immunoglobulin market, a headwind the company has acknowledged while focusing on ASCENIV's more durable growth.
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a broader universe of hundreds of automated strategies that monitor thousands of tickers. Only the top-performing and most relevant bots appear in this section, which is regularly refreshed to reflect changing market conditions. These bots vary in trading approach, holding timeframe, and performance metrics, giving users a way to compare strategies side by side rather than relying on a single methodology. For investors and traders interested in how systematic, data-driven approaches interpret moves like ADMA's recent rally, the page offers a practical starting point for evaluating automated trading ideas.
Looking ahead, the key factors for investors to monitor include the durability of ASCENIV demand and whether favorable utilization trends continue into 2027. Updates to full-year guidance, fourth-quarter results, and commentary on the competitive standard immunoglobulin market will be closely watched, particularly as management has noted signs of stabilization in BIVIGAM utilization.
Pipeline progress on SG-001—including a planned IND submission and potential timelines for a registrational clinical study—represents a meaningful longer-term catalyst. Macroeconomic considerations such as healthcare reimbursement trends, plasma supply dynamics, and broader sector sentiment may also influence the stock. As with any single-stock position, these factors carry risk, and investors should evaluate them alongside their own research and risk tolerance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Moving Average Convergence Divergence (MACD) for ADMA turned positive on November 05, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ADMA as a result. In 65 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +3.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 211 of 255 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.985) is normal, around the industry mean (3.498). P/E Ratio (17.681) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (440.869).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology